Alexander G. Edemskiy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexander G. Edemskiy has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Mikhailovich Chernyavskii
National Medical Research Center named after Academician E.N. Meshalkin; Novosibirsk State Medical University
11 shared publications - Oksana Ya. Vasiltseva
Meshalkin National Medical Research Center
10 shared publications - Denis S. Grankin
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина» Министерства здравоохранения Российской Федерации, Новосибирск
7 shared publications - Dmitry Andreevich Sirota
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Новосибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации
5 shared publications - Elena N. Kliver
Meshalkin National Medical Research Center Moscow Russia
5 shared publications О. Я. Васильцева
ФГБУ «Национальный медицинский исследовательский центр им. акад. Е.Н. Мешалкина» Минздрава России
4 shared publications
Latest Publications
- Open Access
- 18 December 2025
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 29 (3) , 5-17
Predictors of the development of residual pulmonary hypertension in patients with chronic thromboembolic pulmonary hypertension
Introduction. After pulmonary endarterectomy (PEA), a third of patients with chronic thromboembolic pulmonary hypertension (CTEPH) develop residual pulmonary hypertension (PH) in the postoperative period, which plays a decisive role in the formation of long-term mortality, but in modern clinical practice there are no tools for predicting its probability. Objective. of the study was to determine predictors of residual pulmonary hypertension after pulmonary endarterectomy. Methods. The retrospective cohort observational study included 353 patients aged 19 to 77 years with CTEPH who underwent PEA at the Federal State Budgetary Institution "National Medical Research Center named after Academician E.N. Meshalkin" from 2004 to 2019. The patients underwent clinical and instrumental examination before PEA, after PEA during the hospital period and in the late period (12 months) after PEA. An analysis of the obtained factors was carried out, non-modifiable and modifiable predictors of residual PH were determined. Results. According to the regression analysis, independent non-modifiable predictors of residual PH after PEA were identified: history of cancer; blood group AB (IV); reperfusion syndrome after PEA; pulmonary vascular resistance >1000 dyn×s×cm–5 according to pulmonary circulation tensiometry data before PEA; the ratio of the systolic excursion of the tricuspid valve annulus to the systolic pressure in the pulmonary artery 50 mmHg after PEA, measured by transthoracic echocardiography during the hospital period; thrombus calcification in the biopsy material of thrombotic masses. In addition, modifiable predictors were identified - delay in diagnosis and treatment of 6 months or more; obesity; smoking; anemia; irregular warfarin intake; failure to achieve target INR values; thrombosis of veins of any localization after LEE in dynamics. Conclusion. For the first time in Russia, modifiable and non-modifiable predictors of residual PH after PEA in patients with CTEPH were identified. An optimization algorithm for early diagnosis and treatment of CTEPH was proposed.
- 18 December 2025
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 29 (3) , 5-17
Open AccessPredictors of the development of residual pulmonary hypertension in patients with chronic thromboembolic pulmonary hypertension
Introduction. After pulmonary endarterectomy (PEA), a third of patients with chronic thromboembolic pulmonary hypertension (CTEPH) develop residual pulmonary hypertension (PH) in the postoperative period, which plays a decisive role in the formation of long-term mortality, but in modern clinical practice there are no tools for predicting its probability. Objective. of the study was to determine predictors of residual pulmonary hypertension after pulmonary endarterectomy. Methods. The retrospective cohort observational study included 353 patients aged 19 to 77 years with CTEPH who underwent PEA at the Federal State Budgetary Institution "National Medical Research Center named after Academician E.N. Meshalkin" from 2004 to 2019. The patients underwent clinical and instrumental examination before PEA, after PEA during the hospital period and in the late period (12 months) after PEA. An analysis of the obtained factors was carried out, non-modifiable and modifiable predictors of residual PH were determined. Results. According to the regression analysis, independent non-modifiable predictors of residual PH after PEA were identified: history of cancer; blood group AB (IV); reperfusion syndrome after PEA; pulmonary vascular resistance >1000 dyn×s×cm–5 according to pulmonary circulation tensiometry data before PEA; the ratio of the systolic excursion of the tricuspid valve annulus to the systolic pressure in the pulmonary artery 50 mmHg after PEA, measured by transthoracic echocardiography during the hospital period; thrombus calcification in the biopsy material of thrombotic masses. In addition, modifiable predictors were identified - delay in diagnosis and treatment of 6 months or more; obesity; smoking; anemia; irregular warfarin intake; failure to achieve target INR values; thrombosis of veins of any localization after LEE in dynamics. Conclusion. For the first time in Russia, modifiable and non-modifiable predictors of residual PH after PEA in patients with CTEPH were identified. An optimization algorithm for early diagnosis and treatment of CTEPH was proposed.
- Open Access
- 27 April 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Grekov's Bulletin of Surgery
- Vol. 184 (1) , 99-106
Brain protection during aortic arch surgery: current state of problem
Aortic arch surgery is one of the most challenging field of cardiovascular surgery. Reconstructive interventions on the aortic arch are associated with high risks due to the peculiarities of anatomy and technical complexity of surgical intervention. Antegrade cerebral perfusion in combination with hypothermia is widely used to protect the brain during aortic arch surgery. Antegrade cerebral perfusion can be performed in unilateral or bilateral way. Now, there is no clear guidelines regarding the management of patients operated on the aortic arch. This review highlights the main methods of protecting the brain during aortic arch surgery and shows the results of the studies comparing antegrade unilateral brain perfusion with bilateral one. We reviewed rationale of various researchers in choosing two proposed methods to reduce the risk of neurological complications.
- 27 April 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Grekov's Bulletin of Surgery
- Vol. 184 (1) , 99-106
Open AccessBrain protection during aortic arch surgery: current state of problem
Aortic arch surgery is one of the most challenging field of cardiovascular surgery. Reconstructive interventions on the aortic arch are associated with high risks due to the peculiarities of anatomy and technical complexity of surgical intervention. Antegrade cerebral perfusion in combination with hypothermia is widely used to protect the brain during aortic arch surgery. Antegrade cerebral perfusion can be performed in unilateral or bilateral way. Now, there is no clear guidelines regarding the management of patients operated on the aortic arch. This review highlights the main methods of protecting the brain during aortic arch surgery and shows the results of the studies comparing antegrade unilateral brain perfusion with bilateral one. We reviewed rationale of various researchers in choosing two proposed methods to reduce the risk of neurological complications.
- Open Access
- 15 April 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (3) , 279-288
Expert consensus on approaches to risk stratification and choice of therapy in patients with inoperable and residual chronic thromboembolic pulmonary hypertension
On December 13, 2024, the final working group meeting was held, the purpose of which was to discuss the common position of experts on the problem of chronic thromboembolic pulmonary hypertension of various specialties: cardiologists, cardiac surgeons, pulmonologists, on issues of assessing the operability of patients, risk stratification and choice of therapy in patients with inoperable and residual forms of pathology. The discussion field included a wide range of issues that often arise in real clinical practice, but specific answers to them are not given in national and foreign guidelines. On November 8, 2024, at the preparatory stage, 16 experts under the leadership of Academician of the Russian Academy of Sciences I.E. Chazova (chairman) formulated questions for the preparation of a consensus document (without discussion), consistently discussing the feasibility of including each issue in the document and distributing tasks for the final session. Then, at the intermediate stage, experts searched and systematized scientific information on the formulated questions in the PubMed and eLIBRARY systems to prepare sections of the document in accordance with the established tasks. When finalizing the document, experts answered 28 questions: during anonymous voting an individual score was determined for each block from 1 – completely disagree, to 5 – completely agree. It was considered that a strong consensus was achieved with a mean score of M±m 2.5±2, and with a mean score below 2.5, consensus was not achieved. A strong consensus was reached on all issues.
- 15 April 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (3) , 279-288
Open AccessExpert consensus on approaches to risk stratification and choice of therapy in patients with inoperable and residual chronic thromboembolic pulmonary hypertension
On December 13, 2024, the final working group meeting was held, the purpose of which was to discuss the common position of experts on the problem of chronic thromboembolic pulmonary hypertension of various specialties: cardiologists, cardiac surgeons, pulmonologists, on issues of assessing the operability of patients, risk stratification and choice of therapy in patients with inoperable and residual forms of pathology. The discussion field included a wide range of issues that often arise in real clinical practice, but specific answers to them are not given in national and foreign guidelines. On November 8, 2024, at the preparatory stage, 16 experts under the leadership of Academician of the Russian Academy of Sciences I.E. Chazova (chairman) formulated questions for the preparation of a consensus document (without discussion), consistently discussing the feasibility of including each issue in the document and distributing tasks for the final session. Then, at the intermediate stage, experts searched and systematized scientific information on the formulated questions in the PubMed and eLIBRARY systems to prepare sections of the document in accordance with the established tasks. When finalizing the document, experts answered 28 questions: during anonymous voting an individual score was determined for each block from 1 – completely disagree, to 5 – completely agree. It was considered that a strong consensus was achieved with a mean score of M±m 2.5±2, and with a mean score below 2.5, consensus was not achieved. A strong consensus was reached on all issues.
- Open Access
- 1 January 2025
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 40 (4) , e20230441
Surgical Treatment of Pulmonary Artery Angiosarcoma – A Ten-Year Experience
Pulmonary artery angiosarcoma is a rare and extremely severe tumor. Our study summarizes the clinical data of patients treated for pulmonary artery angiosarcoma over the period of 2010-2020. We retrospectively analyzed cases of surgical treatment of patients with diagnosis of pulmonary artery angiosarcoma at our center. Data of operative findings, short-term follow-up, and the long-term results were reviewed where available. The 30-day mortality rate was six (67%) out of nine patients. Three (33%) patients were discharged. Data on pulmonary vascular resistance in the earlyand long-term postoperative periods were assessed if possible. Certain computed tomography signs have been identified that can be used to suspect pulmonary artery angiosarcoma and make a differential diagnosis with chronic thromboembolic pulmonary hypertension. The surgical treatment of choice is pneumonectomy with contralateral pulmonary endarterectomy. Oncological vigilance regarding angiosarcoma in occlusive-stenotic lesions of the pulmonary artery is extremely important. Patients' assessment must be carried out in an expert cardiothoracic surgery center with the involvement of an oncological crew.
- 1 January 2025
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 40 (4) , e20230441
Open AccessSurgical Treatment of Pulmonary Artery Angiosarcoma – A Ten-Year Experience
Pulmonary artery angiosarcoma is a rare and extremely severe tumor. Our study summarizes the clinical data of patients treated for pulmonary artery angiosarcoma over the period of 2010-2020. We retrospectively analyzed cases of surgical treatment of patients with diagnosis of pulmonary artery angiosarcoma at our center. Data of operative findings, short-term follow-up, and the long-term results were reviewed where available. The 30-day mortality rate was six (67%) out of nine patients. Three (33%) patients were discharged. Data on pulmonary vascular resistance in the earlyand long-term postoperative periods were assessed if possible. Certain computed tomography signs have been identified that can be used to suspect pulmonary artery angiosarcoma and make a differential diagnosis with chronic thromboembolic pulmonary hypertension. The surgical treatment of choice is pneumonectomy with contralateral pulmonary endarterectomy. Oncological vigilance regarding angiosarcoma in occlusive-stenotic lesions of the pulmonary artery is extremely important. Patients' assessment must be carried out in an expert cardiothoracic surgery center with the involvement of an oncological crew.
- Open Access
- 25 January 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (1) , 58-62
Therapies of chronic thromboembolic pulmonary hypertension: A review
The article addresses therapies for chronic thromboembolic pulmonary hypertension (CTEPH). The main challenges of patient management at various stages of diagnosis and treatment and the prevalence and pathogenesis of CTEPH are described. Immediate and long-term outcomes after treatment are evaluated. The study aims to present current therapies for CTEPH.
- 25 January 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (1) , 58-62
Open AccessTherapies of chronic thromboembolic pulmonary hypertension: A review
The article addresses therapies for chronic thromboembolic pulmonary hypertension (CTEPH). The main challenges of patient management at various stages of diagnosis and treatment and the prevalence and pathogenesis of CTEPH are described. Immediate and long-term outcomes after treatment are evaluated. The study aims to present current therapies for CTEPH.
- Open Access
- 1 November 2023
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 78 (4) , 297-304
Chronic thromboembolic pulmonary hypertension: epidemiology, diagnosis, treatment — current state of the problem
Chronic thromboembolic pulmonary hypertension is group IV of pulmonary hypertension, which develops with occlusive-stenotic lesions of the pulmonary artery after a pulmonary embolism. There are no clear data on the epidemiology of this disease. At the same time, it is obvious that it is much more widespread than is commonly believed. This is due to the nonspecific clinical picture and the lack of awareness of clinicians about this disease. On the one hand, the pathogenesis of CTEPH is well studied and in many respects similar to pulmonary arterial hypertension, on the other hand, it is not clear why blood clots do not dissolve in a certain percentage of patients. Diagnosis of chronic thromboembolic pulmonary hypertension is fairly well described and should be carried out according to a special algorithm. The treatment of choice is pulmonary endarterectomy. In inoperable patients and patients with residual pulmonary hypertension after surgery, it is possible to perform balloon angioplasty of the pulmonary artery and PAH-specific therapy. In our study, the safety and efficacy of a new method for the treatment of a residual form of chronic thromboembolic pulmonary hypertension, radiofrequency denervation of the pulmonary artery, has been proven. The pathogenetic basis of this technique is the desympathization of the pulmonary circulation by radiofrequency destruction of the autonomic ganglia of the bifurcation of the pulmonary artery and the interruption of the so-called pulmo-pulmonary reflex.
- 1 November 2023
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 78 (4) , 297-304
Open AccessChronic thromboembolic pulmonary hypertension: epidemiology, diagnosis, treatment — current state of the problem
Chronic thromboembolic pulmonary hypertension is group IV of pulmonary hypertension, which develops with occlusive-stenotic lesions of the pulmonary artery after a pulmonary embolism. There are no clear data on the epidemiology of this disease. At the same time, it is obvious that it is much more widespread than is commonly believed. This is due to the nonspecific clinical picture and the lack of awareness of clinicians about this disease. On the one hand, the pathogenesis of CTEPH is well studied and in many respects similar to pulmonary arterial hypertension, on the other hand, it is not clear why blood clots do not dissolve in a certain percentage of patients. Diagnosis of chronic thromboembolic pulmonary hypertension is fairly well described and should be carried out according to a special algorithm. The treatment of choice is pulmonary endarterectomy. In inoperable patients and patients with residual pulmonary hypertension after surgery, it is possible to perform balloon angioplasty of the pulmonary artery and PAH-specific therapy. In our study, the safety and efficacy of a new method for the treatment of a residual form of chronic thromboembolic pulmonary hypertension, radiofrequency denervation of the pulmonary artery, has been proven. The pathogenetic basis of this technique is the desympathization of the pulmonary circulation by radiofrequency destruction of the autonomic ganglia of the bifurcation of the pulmonary artery and the interruption of the so-called pulmo-pulmonary reflex.
- Open Access
- 22 September 2023
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 101 (7-8) , 361-367
Treatment of patients with chronic thromboembolic pulmonary hypertension
The understanding of the tactics for managing patients with pulmonary hypertension (PH) of various etiologies is currently being developed. In August 2022, the European Society of Cardiology adopted new Guidelines for the management of patients with pulmonary hypertension. A separate cohort among them consists of patients with chronic thromboembolic pulmonary hypertension (CTEPH), classifi ed as Group 4 according to the WHO classifi cation. The possibilities of diagnosis, treatment methods, and their availability for this pathology have signifi cantly expanded over the past two decades. The aim of this study is to familiarize physicians with modern methods of treating CTEPH in order to timely refer patients to the most eff ective types of treatment currently available in expert centers in the Russian Federation. Materials and methods. The strategy for searching sources involved analyzing Medline (PubMed) and Scopus databases for the past 20 years using keywords such as diagnostic criteria for chronic thromboembolic pulmonary hypertension, treatment of chronic thromboembolic pulmonary hypertension. To search for additional materials on the topic, the lists of literature in relevant articles and reviews were analyzed.
- 22 September 2023
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 101 (7-8) , 361-367
Open AccessTreatment of patients with chronic thromboembolic pulmonary hypertension
The understanding of the tactics for managing patients with pulmonary hypertension (PH) of various etiologies is currently being developed. In August 2022, the European Society of Cardiology adopted new Guidelines for the management of patients with pulmonary hypertension. A separate cohort among them consists of patients with chronic thromboembolic pulmonary hypertension (CTEPH), classifi ed as Group 4 according to the WHO classifi cation. The possibilities of diagnosis, treatment methods, and their availability for this pathology have signifi cantly expanded over the past two decades. The aim of this study is to familiarize physicians with modern methods of treating CTEPH in order to timely refer patients to the most eff ective types of treatment currently available in expert centers in the Russian Federation. Materials and methods. The strategy for searching sources involved analyzing Medline (PubMed) and Scopus databases for the past 20 years using keywords such as diagnostic criteria for chronic thromboembolic pulmonary hypertension, treatment of chronic thromboembolic pulmonary hypertension. To search for additional materials on the topic, the lists of literature in relevant articles and reviews were analyzed.
- Open Access
- 30 March 2023
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 27 (1) , 38-46
Evaluation of the original sealant with antibacterial effect for synthetic vascular grafts
Background: Vascular graft infection is a severe cardiovascular complication with high mortality rates. Antibacterial vascular graft coatings are widely used and continue to be improved.Objective: To develop a sealant with antimicrobial effect for Dacron vascular grafts and experimentally test the coating properties.Methods: We used 2 types of vascular grafts: graft No. 1 (plain weave) with initial water permeability of 78.8 ± 2.7 mL/cm2/min and graft No. 2 (2/1 twill + 6/4 satin weave) with water permeability of 549.8 ± 20.7 mL/cm2/min. We developed an original gelatin impregnation technique, tested it using a scanning electron microscopy, and measured water permeability and kink radius. We evaluated the antibacterial activity of vancomycin and gelatin impregnation by the disk diffusion test using media with Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 and measured inhibition zones after 24-hour incubation. We used samples cut out of grafts with vancomycin-containing (experimental group) and no vancomycin-containing (control group) impregnation.Results: The gelatin coating of the samples is visualized as a thin even film and provides zero water permeability. On the negative side, it increased stiffness and the kink radius. Thanks to vancomycin added to the coating, bacterial growth significantly inhibits: the mean diameter of the growth inhibition zone for Staphylococcus aureus and Enterococcus faecalis was 15.60 ± 0.65 and 14.40 ± 0.66 mm, respectively. The grafts untreated with vancomycin showed no growth inhibition zones.Conclusion: Vascular graft treatment with gelatin impregnation and vancomycin solution is a simple measure to prevent the growth of gram-positive bacteria on vascular grafts. Received 14 November 2022. Revised 15 December 2022. Accepted 19 December 2022. Funding: The work was supported by Russian Science Foundation (project No. 22-15-20005). Conflict of interest: The authors declare no conflict of interest. Contribution of the authorsConception and study design: I.Yu. Zhuravleva, A.A. Shadanov, D.A. SirotaData collection and analysis: A.A. Shadanov, L.M. Samoylova, S.V. Vladimirov, T.P. Timchenko, N.E. Luchnikov, E.V. KarpovaStatistical analysis: A.A. ShadanovDrafting the article: A.A. Shadanov, L.M. Samoylova, T.P. Timchenko, A.G. EdemskiyCritical revision of the article: D.A. Sirota, I.Yu. Zhuravleva, A.V. Bogachev-Prokofiev, A.M. ChernyavskiyFinal approval of the version to be published: A.A. Shadanov, I.Yu. Zhuravleva, L.M. Samoylova, T.P. Timchenko, S.V. Vladimirov, E.V. Karpova, N.E. Luchnikov, D.A. Sirota, A.G. Edemskiy, A.V. Bogachev-Prokofiev, A.M. Chernyavskiy
- 30 March 2023
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 27 (1) , 38-46
Open AccessEvaluation of the original sealant with antibacterial effect for synthetic vascular grafts
Background: Vascular graft infection is a severe cardiovascular complication with high mortality rates. Antibacterial vascular graft coatings are widely used and continue to be improved.Objective: To develop a sealant with antimicrobial effect for Dacron vascular grafts and experimentally test the coating properties.Methods: We used 2 types of vascular grafts: graft No. 1 (plain weave) with initial water permeability of 78.8 ± 2.7 mL/cm2/min and graft No. 2 (2/1 twill + 6/4 satin weave) with water permeability of 549.8 ± 20.7 mL/cm2/min. We developed an original gelatin impregnation technique, tested it using a scanning electron microscopy, and measured water permeability and kink radius. We evaluated the antibacterial activity of vancomycin and gelatin impregnation by the disk diffusion test using media with Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 and measured inhibition zones after 24-hour incubation. We used samples cut out of grafts with vancomycin-containing (experimental group) and no vancomycin-containing (control group) impregnation.Results: The gelatin coating of the samples is visualized as a thin even film and provides zero water permeability. On the negative side, it increased stiffness and the kink radius. Thanks to vancomycin added to the coating, bacterial growth significantly inhibits: the mean diameter of the growth inhibition zone for Staphylococcus aureus and Enterococcus faecalis was 15.60 ± 0.65 and 14.40 ± 0.66 mm, respectively. The grafts untreated with vancomycin showed no growth inhibition zones.Conclusion: Vascular graft treatment with gelatin impregnation and vancomycin solution is a simple measure to prevent the growth of gram-positive bacteria on vascular grafts. Received 14 November 2022. Revised 15 December 2022. Accepted 19 December 2022. Funding: The work was supported by Russian Science Foundation (project No. 22-15-20005). Conflict of interest: The authors declare no conflict of interest. Contribution of the authorsConception and study design: I.Yu. Zhuravleva, A.A. Shadanov, D.A. SirotaData collection and analysis: A.A. Shadanov, L.M. Samoylova, S.V. Vladimirov, T.P. Timchenko, N.E. Luchnikov, E.V. KarpovaStatistical analysis: A.A. ShadanovDrafting the article: A.A. Shadanov, L.M. Samoylova, T.P. Timchenko, A.G. EdemskiyCritical revision of the article: D.A. Sirota, I.Yu. Zhuravleva, A.V. Bogachev-Prokofiev, A.M. ChernyavskiyFinal approval of the version to be published: A.A. Shadanov, I.Yu. Zhuravleva, L.M. Samoylova, T.P. Timchenko, S.V. Vladimirov, E.V. Karpova, N.E. Luchnikov, D.A. Sirota, A.G. Edemskiy, A.V. Bogachev-Prokofiev, A.M. Chernyavskiy
- Open Access
- 4 February 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 24 (12) , 876-871
Stenosis of the trunk of the left coronary artery in idiopathic pulmonary hypertension. Case report
The manuscript presents a clinical case of treatment of a patient with idiopathic pulmonary hypertension and a rare complication left main coronary artery stenosis caused due to compression by the dilated pulmonary artery. This complication was clinically manifested by chest pain. The patient underwent percutaneous coronary angioplasty with stenting of the left main coronary artery and subsequent prescription of combined PAH-specific therapy. During the late follow-up examination in addition to clinical improvement and the absence of pain, 6-minute walking test distance increase, positive dynamics of echocardiography, right heart catheterization, as well as the laboratory marker of heart failure NT-proBNP were noted.
- 4 February 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 24 (12) , 876-871
Open AccessStenosis of the trunk of the left coronary artery in idiopathic pulmonary hypertension. Case report
The manuscript presents a clinical case of treatment of a patient with idiopathic pulmonary hypertension and a rare complication left main coronary artery stenosis caused due to compression by the dilated pulmonary artery. This complication was clinically manifested by chest pain. The patient underwent percutaneous coronary angioplasty with stenting of the left main coronary artery and subsequent prescription of combined PAH-specific therapy. During the late follow-up examination in addition to clinical improvement and the absence of pain, 6-minute walking test distance increase, positive dynamics of echocardiography, right heart catheterization, as well as the laboratory marker of heart failure NT-proBNP were noted.
- Open Access
- 7 October 2021
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 36 (3) , 154-160
Chronic thromboembolic pulmonary hypertension in an obese patient with type 2 diabetes mellitus
Metabolic disorders represent a serious medical and social problem and are risk factors for the development of thromboembolic complications. Disturbances of both carbohydrate and fat metabolism contribute to an increase in blood viscosity, creating prothrombotic conditions, which are not always objectively assessed even by specialists. In addition, multiple comorbid conditions usually significantly complicate the prognosis. The article presents a clinical case of recurrent thrombosis of the right atrium and the orifices of the superior and inferior vena cava in a 39-year-old patient with type 2 diabetes mellitus, obesity, arterial hypertension, and varicose vein disease.
- 7 October 2021
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 36 (3) , 154-160
Open AccessChronic thromboembolic pulmonary hypertension in an obese patient with type 2 diabetes mellitus
Metabolic disorders represent a serious medical and social problem and are risk factors for the development of thromboembolic complications. Disturbances of both carbohydrate and fat metabolism contribute to an increase in blood viscosity, creating prothrombotic conditions, which are not always objectively assessed even by specialists. In addition, multiple comorbid conditions usually significantly complicate the prognosis. The article presents a clinical case of recurrent thrombosis of the right atrium and the orifices of the superior and inferior vena cava in a 39-year-old patient with type 2 diabetes mellitus, obesity, arterial hypertension, and varicose vein disease.